» Articles » PMID: 31519061

Hydrogen-deuterium Exchange Mass Spectrometry Highlights Conformational Changes Induced by Factor XI Activation and Binding of Factor IX to Factor XIa

Overview
Publisher Elsevier
Specialty Hematology
Date 2019 Sep 14
PMID 31519061
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Factor XI (FXI) is a zymogen in the coagulation pathway that, once activated, promotes haemostasis by activating factor IX (FIX). Substitution studies using apple domains of the homologous protein prekallikrein have identified that FIX binds to the apple 3 domain of FXI. However, the molecular changes upon activation of FXI or binding of FIX to FXIa have remained largely unresolved.

Objectives: This study aimed to gain more insight in the FXI activation mechanism by identifying the molecular differences between FXI and FXIa, and in the conformational changes in FXIa induced by binding of FIX.

Methods: Hydrogen-deuterium exchange mass spectrometry was performed on FXI, FXIa, and FXIa in complex with FIX.

Results: Both activation and binding to FIX induced conformational changes at the interface between the catalytic domain and the apple domains of FXI(a)-more specifically at the loops connecting the apple domains. Moreover, introduction of FIX uniquely induced a reduction of deuterium uptake in the beginning of the apple 3 domain.

Conclusions: We propose that the conformational changes of the catalytic domain upon activation increase the accessibility to the apple 3 domain to enable FIX binding. Moreover, our HDX MS results support the location of the proposed FIX binding site at the beginning of the apple 3 domain and suggest a mediating role in FIX binding for both loops adjacent to the apple 3 domain.

Citing Articles

The Light Chain Allosterically Enhances the Protease Activity of Murine Urokinase-Type Plasminogen Activator.

Torres-Paris C, Song H, Engelberger F, Ramirez-Sarmiento C, Komives E Biochemistry. 2024; 63(11):1434-1444.

PMID: 38780522 PMC: 11154964. DOI: 10.1021/acs.biochem.4c00071.


Capturing the Dynamic Conformational Changes of Human Isocitrate Dehydrogenase 1 (IDH1) upon Ligand and Metal Binding Using Hydrogen-Deuterium Exchange Mass Spectrometry.

Sabo K, Albekioni E, Caliger D, Coleman N, Thornberg E, Avellaneda Matteo D Biochemistry. 2023; 62(6):1145-1159.

PMID: 36854124 PMC: 10089636. DOI: 10.1021/acs.biochem.2c00636.


HK is the apple of FXI's eye.

Moellmer S, Puy C, McCarty O J Thromb Haemost. 2022; 20(11):2485-2487.

PMID: 36271466 PMC: 9589922. DOI: 10.1111/jth.15842.


Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen.

Bar Barroeta A, Marquart J, Bakhtiari K, Meijer A, Urbanus R, Meijers J J Thromb Haemost. 2022; 20(11):2538-2549.

PMID: 35815349 PMC: 9795894. DOI: 10.1111/jth.15815.


Basic science research opportunities in thrombosis and hemostasis: Communication from the SSC of the ISTH.

Mutch N, Walters S, Gardiner E, McCarty O, De Meyer S, Schroeder V J Thromb Haemost. 2022; 20(6):1496-1506.

PMID: 35352482 PMC: 9325489. DOI: 10.1111/jth.15718.


References
1.
Navaneetham D, Jin L, Pandey P, Strickler J, Babine R, Abdel-Meguid S . Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2. J Biol Chem. 2005; 280(43):36165-75. DOI: 10.1074/jbc.M504990200. View

2.
Meijers J, Tekelenburg W, Bouma B, Bertina R, Rosendaal F . High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000; 342(10):696-701. DOI: 10.1056/NEJM200003093421004. View

3.
Yang D, Flanders M, Kim H, Rodgers G . Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol. 2006; 126(3):411-5. DOI: 10.1309/QC259F09UNMKVP0R. View

4.
Doggen C, Rosendaal F, Meijers J . Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood. 2006; 108(13):4045-51. DOI: 10.1182/blood-2005-12-023697. View

5.
Lowenberg E, Meijers J, Monia B, Levi M . Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost. 2010; 8(11):2349-57. DOI: 10.1111/j.1538-7836.2010.04031.x. View